ANDA 40888, held by Sagent Pharmaceuticals. Methylprednisolone Sodium Succinate.
As of Nov 21, 2026, ANDA 40888 (Methylprednisolone Sodium Succinate), held by Sagent Pharmaceuticals, was first approved by FDA on Jul 18, 2011, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 18, 2011 | Original application | Approved | None posted |
| Methylprednisolone Sodium SuccinateEQ 40MG BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Rx |
| Methylprednisolone Sodium SuccinateEQ 125MG BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Rx |
| Methylprednisolone Sodium SuccinateEQ 500MG BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Rx |
| Methylprednisolone Sodium SuccinateEQ 1GM BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Rx |
| Methylprednisolone Sodium SuccinateEQ 2GM BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Rx |
| Feb 14, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 14, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 14, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 18, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters